In the article entitled “St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference” [Breast Care. 2025; DOI: 10.1159/000546080] by Ditsch et al., the members of the scientific committee of the 2025 St. Gallen International Breast Cancer Conference had not been listed.
The first paragraph of the Introduction should correctly read as follows:
Introduction
The St. Gallen Conference takes place every 2 years in Vienna, Austria. In 2025, it was held from March 12th–15th, with the largest attendance since the pandemic, more than 3,000 participants from over 100 countries. Members of the Scientific Committee this year were Harold Burstein, Boston, MA, USA; David Cameron, Edinburgh, UK; Giuseppe Curigliano, Milan, Italy; Carsten Denkert, Marburg, Germany; Michael Gnant, Vienna, Austria; Sherene Loi, Melbourne, VIC, Australia; Sibylle Loibl, Neu-Isenburg, Germany; Philip Poortmans, Antwerp, Belgium; Meredith Regan, Boston, MA, USA; Beat Thürlimann, St. Gallen, Switzerland; Walter Weber, Basel, Switzerland. The conference chairs Univ. Prof. Dr. Michael Gnant (Medical University of Vienna, Austria), Prof. Dr. Sibylle Loibl (Goethe University Frankfurt/Main, German Breast Group [GBG] Forschungs GmbH, Neu-Isenburg, Germany), Prof. Dr. Med. Beat Thürlimann (Breast Center, Kantonsspital St. Gallen and SwissBreastCare, Bethanienspital, Zurich, Switzerland) and Prof. Dr. Walter Weber (University Hospital Basel, Switzerland) professionally guided through the program on Early Breast Cancer, featuring abstracts submitted from all over the world. In addition, Prof. Dr. Herold J. Burstein (USA) led the panel through difficult topics in an excellent, clearly structured and engaging way. Almost 80 experts from all continents and more than 30 nations formed the panel and summarized the current literature in excellent presentations and discussions. Final voting covered the topics of genetic testing, DCIS, breast and axillary surgery, radiation therapy, systemic treatment based on subtypes, treatment of elderly, therapy of local-regional recurrence, and oligometastatic breast cancer.